Affiliations 

  • 1 Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
  • 2 Center for Human Proteomics, Royal College of Surgeons in Ireland, Dublin, Ireland. ; School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland. ; Royal College of Surgeons in Ireland, Dublin, Ireland
  • 3 Department of Pathology, University of Wüerzburg, Wüerzburg, Germany
  • 4 Department of Microbiology and Immunology, College of Medicine, University of Mosul, Iraq
  • 5 Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia
  • 6 Center for Human Proteomics, Royal College of Surgeons in Ireland, Dublin, Ireland
  • 7 Monoclonal Antibodies Unit, Biotechnology Programme, Spanish National Cancer Research Center, Madrid, Spain
  • 8 Department of Hematology, John Radcliffe Hospital, Oxford, UK
Biomark Insights, 2014;9:77-84.
PMID: 25232277 DOI: 10.4137/BMI.S16553

Abstract

FAS-associated protein with death domain (FADD) is a major adaptor protein involved in extrinsic apoptosis, embryogenesis, and lymphocyte homeostasis. Although abnormalities of the FADD/death receptor apoptotic pathways have been established in tumorigenesis, fewer studies have analyzed the expression and role of phosphorylated FADD (pFADD). Our identification of FADD as a lymphoma-associated autoantigen in T-cell lymphoma patients raises the possibility that pFADD, with its correlation with cell cycle, may possess role(s) in human T-cell lymphoma development. This immunohistochemical study investigated pFADD protein expression in a range of normal tissues and lymphomas, particularly T-cell lymphomas that require improved therapies. Whereas pFADD was expressed only in scattered normal T cells, it was detected at high levels in T-cell lymphomas (eg, 84% anaplastic large cell lymphoma and 65% peripheral T cell lymphomas, not otherwise specified). The increased expression of pFADD supports further study of its clinical relevance and role in lymphomagenesis, highlighting phosphorylation of FADD as a potential therapeutic target.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.